MAP — Microba Life Sciences Balance Sheet
0.000.00%
- AU$38.63m
- AU$30.98m
- AU$15.67m
- 28
- 55
- 13
- 22
Annual balance sheet for Microba Life Sciences, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | R2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 13 | 26.4 | 31.1 | 21.1 | 10.9 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1.65 | 3.42 | 7.24 | 8.1 | 4.11 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 16.2 | 35.8 | 41.5 | 32.2 | 19 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.2 | 2.81 | 2.58 | 3.91 | 3.87 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Total Assets | 18.5 | 39.5 | 47 | 58.7 | 47.4 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.35 | 5.26 | 7.82 | 12.4 | 10.2 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 3.55 | 5.94 | 8.38 | 17.5 | 14.9 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 14.9 | 33.5 | 38.6 | 41.2 | 32.5 |
| Total Liabilities & Shareholders' Equity | 18.5 | 39.5 | 47 | 58.7 | 47.4 |
| Total Common Shares Outstanding |